Figure 2.

Cellular delivery of STING agonists using bMSN. a) TEM image of bMSN. b) Degradation of bMSN in a physiological condition (Krebs-Henseleit solution at 37 °C). c) Surface charge and d) hydrodynamic size of bMSN measured before and after amine-modification using dynamic light scattering (DLS). Particles were transferred to water for measurements. e) CDA-loading capacity of bMSN. f) CDA Release profiles in different pH conditions. g,h) Uptake of CDA by BMDCs assessed in vitro with g) flow cytometry and h) confocal microscopy. i) Activation of BMDCs measured by flow cytometry after 4 h of incubation. j) STING activation of human monocyte-derived THP1-Blue ISG cells measured after overnight incubation. All data are presented as mean ± SEM, showing representative results from two independent studies with n = 3, with an exception of g) with n = 1. Scale bars in a,b) = 100 nm and h) = 5 μm. **P < 0.01, *** P < 0.001, ****P < 0.0001 analyzed by one-way or two-way ANOVA with Tukey’s honestly significant difference (HSD) multiple comparison post hoc test.